HLB has vowed to seek approval with the U.S. Food and Drug Administration (FDA) again quickly for its liver cancer drug Rivoceranib following the FDA s rejection on Friday, but it is unclear whether the drug will be approved next time, .
Weight loss drugs in the spotlight as investors inject $400 million into new biotech startup proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
South Korean drugmaker HLB hit by US FDA's rejection of Rivoceranib liver cancer drug koreatimes.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreatimes.co.kr Daily Mail and Mail on Sunday newspapers.
HLB’s Rivoceranib anti-cancer drug recently received approval in China as a treatment for ovarian cancer, paving the way for the company to expand the drug s uses in the global market, the company said Monday.